Amanda is involved with the DTRF as an advocate as well as a volunteer collaborator in the first international, natural history study and desmoid tumor patient registry, which is in collaboration with the National Organization for Rare Disorders (NORD). She joined RRD International LLC as a clinical project manager, where she supports the overall and daily clinical operations activities on behalf of RRD’s partners for clinical trials. She has a passion to serve patients with serious or unmet medical needs by helping to make potential therapies and treatments accessible to them.
Amanda is a graduate of Clemson University with a B.S. in Biological Sciences and was chosen in 2008 to participate in the Alta Bates Oncology Preceptorship in Berkeley CA. Now, she has more than 12 years of clinical research experience primarily in the early phase development of assets, including large and small molecules, across various therapeutic areas.
Most notably, Amanda was part of a small clinical team responsible for data collection and on-time database closure of a pivotal Phase 2/3 trial to enable fast-tracked FDA approval. She was part of the initial team, working with Regeneron Pharmaceuticals, in the start-up of an international Phase 1/2 program, and a year later, she was recruited into Amgen’s Early Development Department as a Clinical Research Study Manager in Thousand Oaks, CA.
